Effects of dapagliflozin on cardiovascular outcomes in type 2 diabetes: Study protocol of a randomized controlled trial

BACKGROUND: Dapagliflozin, a novel inhibitor of renal sodium-glucose cotransporter 2, allows an insulin-independent approach to improve type 2 diabetes hyperglycemia. This current research is a double blinded, randomized, and prospective trial to determine the effect of dapagliflozin on cardiovascul...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Dong, Hui, Yuan, Yang, Chuanhui, Xu, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
4300
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7544418/
https://www.ncbi.nlm.nih.gov/pubmed/33031329
http://dx.doi.org/10.1097/MD.0000000000022660

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7544418/
https://www.ncbi.nlm.nih.gov/pubmed/33031329
http://dx.doi.org/10.1097/MD.0000000000022660

Ejemplares similares